German pharmaceutical company URSAPHARM expands to Greece

The German pharmaceutical company URSAPHARM is investing in Greece, launching commercial operations in January 2026 through the establishment of a subsidiary in Greece and Cyprus, under the leadership of Managing Director Greece & Cyprus Ioannis Bessis.

URSAPHARM was founded in 1974 as a family business by two pharmacists. Today, Frank Holzer and Dominik Holzer, who lead the company, represent the second and third generations managing the family enterprise. Since its establishment, the company has evolved into a globally operating group with innovative products and patents, employing more than 1,200 people worldwide.

With its own subsidiaries in France, the Benelux countries, Austria, Poland, the Czech Republic, Slovakia, Portugal, Russia, India, Italy, Serbia and Switzerland, as well as partnerships with distribution partners in more than 80 countries, URSAPHARM has developed into a truly global player, reporting sales of 400 million euros in 2025 and annual growth of 8%–12%.

In Greece, its initial product offering includes the HYLO ophthalmic range, with additional products from its portfolio expected to follow shortly. Beyond treatments for eye conditions, the company’s portfolio also includes general medicine products for the nasal mucosa, seasonal allergies, dietary supplements and dermocosmetics.

According to Bessis, the company aims to build partnerships with the scientific community and expand its portfolio, while an additional country is expected to be included under this management structure alongside Greece and Cyprus.